Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Twenty Pneumococcal Serotyping Methods Evaluated

By LabMedica International staff writers
Posted on 30 Nov 2015
A pneumococcal serotyping method suitable for use in carriage studies should have high sensitivity, including the ability to detect multiple serotypes, detect most or all serotypes, be suitable to scale up for large projects, and be practical for resource-poor countries. More...


About 800,000 young children, mostly living in low-income countries, die annually from pneumococcal diseases and vaccine development requires accurate carriage studies with high sensitivity and the ability to detect multiple serotypes in individual samples. Pneumococcal disease is caused by the Streptococcus pneumoniae bacterium.

A team of scientists led by those at the Murdoch Childrens Research Institute (Parkville, Australia) established the PneuCarriage project, a large, international multicenter study dedicated to the identification of the best pneumococcal serotyping methods for carriage studies. The team distributed reference sample sets to 15 research groups for blinded testing. Twenty pneumococcal serotyping methods were used to test 81 laboratory-prepared spiked) samples. The five top-performing methods were used to test 260 nasopharyngeal field samples collected from children in six high-burden countries. Sensitivity and positive predictive value (PPV) were determined for the test methods and the reference method which is traditional serotyping of more than 100 colonies from each sample.

Fifteen methods detected the major serotype in the spiked samples with equal to or greater than 70% sensitivity, but only eight detected minor serotypes at the same threshold. For the field samples, a culture microarray method had the best overall performance (95.8% sensitivity and 93.9% PPV), while a more affordable culture and latex sweep method that has been used in low-income settings showed promising performance (79.8% sensitivity and 91.4% PPV). The 260 field samples contained 307 serotypeable pneumococci. Forty-nine of the known 97 serotypes, including 12 of the pneumococcal conjugate vaccine 13 (PCV13) types, were identified at least once. PCV7, PCV10, and PCV13 types represented 27.1%, 29.0%, and 45.6% of the 307 serotypeable pneumococci, respectively. Serotypes 19F, 23F, 6A, 15B/C, 19A, 14, 16F, 6C, 11A, 13, and 6B were the most common and together accounted for 68% of the total.

The authors concluded that that although most of the recently developed serotyping methods detected the dominant serotype in a sample, many failed to detect minor serotypes. Moreover, the performance of similar methods varied markedly, and methods optimized for testing pure isolates did not necessarily work well when testing more complex samples. These findings identified microarray with a culture amplification step as the top-performing method, but, importantly, this study did not test all the available serotyping methods. The study was published on November 17, 2015, in the journal Public Library of Science Medicine.

Related Links:

Murdoch Childrens Research Institute 



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.